Treatment of Metabolic Diseases with 5-Aminolevulinate Synthase Inhibitors

Competitive Advantages

  • Effectively inhibits ALAS
  • Treats heme biosynthesis disorders and other ALAS related diseases
  • Easy synthesis and purification technique

Summary

USF scientists have discovered inhibitors against 5-aminolevulinate synthase. This was achieved via a kinetic target -guided synthesis that was extended to multi-fragment screening with increased throughput. This invention provides novel molecules that are effective in treatment of diseases and metabolic disorders associated with 5-aminolevulinate synthase. It has the potential to treat heme biosynthesis disorder like porphyrias, hepatic disorders, and erythropoietic disorders. 

Multi-Fragment Screening Traces and Activity

Desired Partnerships

  • License
  • Sponsored Research
  • Co-Development

 

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
5-Aminolevulinate Synthase Inhibitors and Methods of Use Thereof Nationalized PCT United States 16/625,363 11,479,532 6/21/2018 10/25/2022 1/16/2039